|
Drug Watch International MARIJUANA
RESEARCH REVIEW
Marijuana
causes aspergillosis
in kidney
transplant patient A
48-year-old successful kidney transplant patient who heavily used marijuana
immediately following his transplant developed invasive pulmonary aspergillosis
(IPA), a fungus transmitted in the smoke of marijuana. Marks et al reported on
their use of an experimental antifungal drug to effectively treat this life
threatening condition (Transplantation,
Vol.61, 1771-1773, No. IQ June 27,1996), and noted that IPA "is a devastating
complication in the immuno-compromised patient" such as patients with AIDS,
chronic granulomatous disease, bone marrow transplants and those receiving
chemotherapy for small cell lung cancer. Aspergillosis has up to a 90% fatality
rate if contracted by transplant patients. Commentary: Marijuana was the only risk
factor for IPA in this patient who was a marijuana smoker prior to
transplantation. The researchers stated that transplant patients should be
strongly warned against the use of marijuana following surgery or during periods
when they are being medicated with high doses of steroids and other drugs used
to suppress rejection of the transplant. ## Even
infrequent marijuana use impairs cognitive skills Long
term use of marijuana is known to result in progressively impaired ability to
process complex information. Solowij of the National Drug and Alcohol Research
Center in Syndey, Australia, examined whether cessation of marijuana use would
normalize the intellectual performance of users. (Life Sciences, Vol.56, pp.2119-2126, 1995) Subjects
were recruited from the general community by advertising. To be included, Sophisticated
auditory testing, which required reaction to a variety of stimuli, was compared
in 16 long-term users, 16 short term users, 28 ex-users, and 16 age and sex
matched controls. All marijuana users had abnormal reactions compared to the
controls. Reaction time was 11% longer in long-term users, 11% longer in
short-term users, and did not return to normal even after six months of
abstinence. Commentary: This study confirms that
marijuana use produces difficulty in complex brain functions and, more
disturbingly, even after up to six months of abstinence these effects were still
present. A companion paper (Life Sciences,
Vol.56 pp. 2127-2134,1995) by Solowij et al, reports that the brain
event-related measures normalize during acute marijuana intoxication, suggesting
a basis for the physical dependence component of marijuana use. ## Study
implicates THC in suppression of immune system response The
major psychoactive component of marijuana, delta-9 THC, has been shown in human
and experimental animals to affect the immune system. Freidman et al in Advances
in Experimental and Medical Biology Vol.373, pp. 103-113,1996, present
studies in mice given THC. These mice have reduced antibody formulation and
abnormalities of other chemicals which help the body fight viral and bacterial
infection. When these mice are exposed to a bacteria, Legionella pneumophila, a
rapid toxic shock-like death occurs - within one day. Commentary: Individuals who chronically
use marijuana may be more subject to adverse reaction to common bacteria and
viruses in the environment than non-users. This correlates with the study by
Polen, et al as reported in the Western
Journal of Medicine, June1993, which found that "Daily marijuana
smoking, even in the absence of tobacco, appeared to be associated with an
elevated risk of health care use for various health problems. ## Study
describes cannabis dependence Lundqvist,
Life Science, Vol.56 pp. 2145-2150 1995, tested
patients in treatment for chronic cannabis use with a standard psychological
instrument to determine "which patients showed improvement in manageability
and meaningfulness of life". Twenty patients were drug-free for 40 days
or more, but none had undergone treatment. Thirty-one other patients were tested
after being drug free for two weeks, and a third group of 15 patients was tested
before and after six weeks of treatment. For comparison, nine patients on
methadone maintenance, 62 former poly-drug users, and 26 counselors were also
tested. Some
improvement was demonstrated in the group that underwent treatment, and post
treatment scores were in the range of the control subjects. Users who had not
participated in therapy had lower scores. Both patients in methadone programs
and former poly-drug users who had undergone psycho-social treatment had scores
below normal. Commentary: Again,
impaired cognitive skills and functioning were documented in chronic cannabis
users. These changes create "a new state of consciousness that can be
described as a cannabis dependent effect." It takes 14 days of abstinence before a user is able to
control the processes of cognitive functioning, and it takes up to six weeks
before a user is able to make complex intellectual decisions that are normal.
Weaknesses occur in comprehension, classifying information correctly,
differentiating Marijuana
use associated with Antisocial Personality Disorder Scherrer
et al (The Journal of Nervous and Mental
Disease,
Vol.184,
No.10) studied Antisocial Personality Disorder (ASP) in 1874 pairs of identical
male twins who were veterans from the Vietnam era. When twins were randomly
selected, 8 out of 10 ASP symptoms were more prevalent in persons with a
lifetime history of marijuana use compared to those twins who had never used
drugs. Reckless
regard for their own or others safety and failure to conform to social norms
were 2.5 to 3 times more likely in marijuana-using twins compared to their
non-using twin brother. Some of this was explained by concomitant alcohol abuse
and combat in Vietnam, but marijuana users were still 2.5 times more likely to
fail to observe lawful behavior than their twins. Commentary: Identical twins have the same
genetic makeup. This study clearly shows that marijuana use is not an inherited
weakness but instead that drug use causes antisocial personality traits and
symptoms. ## INTERNET
SITES FOR MORE INFORMATION ON http://www.drugfreeworkplace.org ------------------------------ Material used in this
publication has been reviewed and commented on by William M. Bennett, M.D.,
Professor of Medicine, Division of Nephrology, Clinical Pharmacology and
Hypertension at Oregon Health Sciences University, Portland, Oregon Drug
Watch Oregon
This page was last updated on July 03, 2001 |